Isolation and characterization of plasminogen activators from hyperlastic and malignant prostate tissue

Kirchheimer, Johannes C.; Koller, A E; Binder, Bernd R.

doi:10.1016/0304-4165(84)90129-6

Cited by 56 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To obtain information as to whether the plasminogen activators demonstrated in prostatic hyperplasia and prostatic carcinoma have similarities besides their molec ular weights, plasminogen activators were purified from individual extracts of prostatic hyperplasia and prostatic carcinoma by means of the method described [23], From hyperplasia as well as carcinoma tissues plasminogen activators could be purified from both source materials to homogeneity, both exhibiting immunological and physi cochemical characteristics of high molecular weight hu man urokinase (fig. 4).…”

Section: H Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Tissue Plasminogen Activator Activity in Prostatic Cancer

Koller¹,

Kirchheimer²,

Pflüger³

et al. 1984

Eur Urol

View full text Add to dashboard Cite

Section: H Resultsmentioning

confidence: 99%

“…Furthermore it was attempted to correlate fibrinolytic activity in pros tatic carcinoma with the degree of malignancy, the tumor stage and the metastatic spread. The detailed procedure for purification of plasminogen activator from prostate tissue will be published elsewhere [23].…”

Section: Introductionmentioning

confidence: 99%

Tissue Plasminogen Activator Activity in Prostatic Cancer

Koller¹,

Kirchheimer²,

Pflüger³

et al. 1984

Eur Urol

View full text Add to dashboard Cite

“…Similar results were obtained with par tially purified prostate tumor plasminogen activators from rats untreated and treated with D-Trp6-LH-RH. Recently Kirchheimer et al [35] isolated from human malignant prostate tissue two plasminogen activators, 80% has properties of urokinase-type and 20% of tissue-type.…”

Section: Discussionmentioning

confidence: 99%

An Inhibitor of Urokinase and Tissue Plasminogen Activators in Dunning R3327H Prostate Tumors of Rats Treated with D-Trp6-LH-RH

Hierowski

1985

Horm Res

View full text Add to dashboard Cite

The antifibrinolytic activity of cytosol from Dunning R3327H rat prostate tumors was studied. The prostate tumors from rats treated with D-Trp⁶-LH-RH had 2.5 times lower plasminogen activator activity than tumors from untreated rats. This was due to the presence of an inhibitor of plasminogen activator as well as a reduction in residual activity of plasminogen activator(s). Only the cytosolic extracts from prostate tumors of rats treated with D-Trp⁶-LH-RH contained this inhibitor. The purified inhibitor (m.w. 21,000), formed a complex with urokinase and partially purified plasminogen activator(s) from prostate tumors of untreated as well as D-Trp⁶-LH-RH treated rats. The increase in antifibrinolytic activity after treatment with LH-RH analogs may be an important factor in reducing the invasiveness of the prostate tumor.

show abstract

“…Recently, it was shown that tissue extracts of hyperplastic as well as carci nomatous prostate glands contain PAA in hibitable by anti-u-PA1 IgG to about 80%, while a mixture of anti-u-PA IgG and antit-PA1 IgG completely abolished PAA in the extracts. As expected, total PAA in extracts of carcinomatous prostate tissue was signifi cantly higher [4]. It was the aim of this study 1 The nomenclature urokinase-type plasminogen ac tivator (u-PA) and tissue-type plasminogen activator (t-PA) was adopted by the Subcommittee of Fibrinoly sis at the XXVIIIth Meeting of the International Com mittee on Thrombosis and Haemostasis, Bergamo 1982. to attribute the production of these two plas minogen activators to histological structures in the hyperplastic and carcinomatous pros tate gland.…”

Section: Introductionmentioning

confidence: 99%

Localization and Immunological Characterization of Plasminogen Activators in Human Prostate Tissue

Kirchheimer¹,

Binder²

1983

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

In tissue sections of human hyperplastic as well as carcinomatous prostate glands ñbrinolytic activity could be attributed to collecting ducts and vessel walls. Inhibition studies with antibodies directed against human urokinase (u-PA) or tissue plasminogen activator (t-PA) revealed the presence of a plasminogen activator completely inhibitable by anti-t-PA IgG in the vessel walls, while in collecting ducts the plasminogen activator activity was inhibited by anti-u-PA IgG to only 80% and by anti-t-PA IgG to about 20%. A mixture of anti-u-PA and anti-t-PA IgG was able to inhibit fibrinolytic activity in collecting ducts completely. In carcinomatous prostate glands total fibrinolytic activity was significantly higher, but localization and relative contribution of anti-u-PA-inhibitable and anti-t-PA-inhibitable plasminogen activators remained the same.

show abstract

Isolation and characterization of plasminogen activators from hyperlastic and malignant prostate tissue

Cited by 56 publications

References 19 publications

Tissue Plasminogen Activator Activity in Prostatic Cancer

Tissue Plasminogen Activator Activity in Prostatic Cancer

An Inhibitor of Urokinase and Tissue Plasminogen Activators in Dunning R3327H Prostate Tumors of Rats Treated with <i>D</i><i>-</i>Trp<sup>6</sup>-LH-RH

Localization and Immunological Characterization of Plasminogen Activators in Human Prostate Tissue

Contact Info

Product

Resources

About